Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Immune-mediated Pathogenesis and Therapies for Inflammatory Autoimmune Diseases

Author(s): Md. Asiful Islam, Mohammad A. Kamal, Abu H. Md Zulfiker and Siew H. Gan

Volume 25 , Issue 27 , 2019

Page: [2907 - 2908] Pages: 2

DOI: 10.2174/138161282527191007151037

[1]
Tsay G, Zouali M. The interplay between innate-like B cells and other cell types in autoimmunity. Front Immunol 2018; 9: 1064.
[2]
Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev 2012; 11: 754-65.
[3]
Sahebari M, Rezaieyazdi Z, Khodashahi M. Selenium and autoimmune diseases: A review article. Curr Rheumatol Rev 2019; 15: 123-34.
[4]
Aiello A, Candore G, Accardi G, et al. Translation of basic research into clinics: Killer Immunoglobulin-like receptors genes in autoimmune and infectious diseases. Curr Pharm Des 2018; 24: 3113-22.
[5]
Nalli C, Somma V, Andreoli L, et al. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun Highlights 2018; 9: 1-6.
[6]
Abdel-Maksoud MA, Al-Quraishy S. Autoimmune diseases and infections: A controversial relationship. Curr Immunol Rev 2018; 14: 60-5.
[7]
Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med 2018; 168: 121-30.
[8]
Yi L, Weifan Y, Huan Y. Chimeric antigen receptor-engineered regulatory T lymphocytes: Promise for immunotherapy of autoimmune disease. Cytotherapy 2019; pii: S1465-3249(19): 30750-759.
[9]
Patra MC, Shah M, Choi S. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Semin Cancer Biol 2019.
[http://dx.doi.org/10.1016/j.semcancer.2019.05.002]
[10]
Giemza-Stokłosa J, Islam MA, Kotyla PJ. Hyperferritinaemia: An iron sword of autoimmunity. Curr Pharm Des 2019; 25(27): 2909-18.
[11]
Cavestro C, Ferrero M, Mandrino S, Tavi MD, Rota E. Novelty in inflammation and immunomodulation in migraine. Curr Pharm Des 2019; 25(27): 2919-36.
[12]
Khan MA, Khurana N, Ahmed RS, et al. Chemokines: A potential therapeutic target to suppress autoimmune arthritis. Curr Pharm Des 2019; 25(27): 2937-46.
[13]
Kechida M. Update on autoimmune diseases pathogenesis. Curr Pharm Des 2019; 25(27): 2947-52.

© 2022 Bentham Science Publishers | Privacy Policy